|
Friday, December 10, 2021, Atlanta, GA, 3:15 PM – 5:15 PM Eastern Time
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma (Part 3 of a 4-Part Series)A Friday Satellite Symposium and Virtual Event Preceding the 63rd ASH Annual Meeting
Location
Omni Atlanta Hotel at CNN Center 190 Marietta St NW Atlanta, GA 30303 Hotel Phone: (404) 659-0000 Program Schedule — Eastern Time 3:00 PM – 3:15 PM — Registration and Snacks 3:15 PM – 5:15 PM — Educational Meeting Meeting Room International Ballroom (E-F) - North Tower (M2 Floor) This event will be webcast live. Please see Registration tab for details. Faculty
Larry D Anderson Jr, MD, PhD Associate Professor Director of Myeloma, Waldenström’s, and Amyloidosis Program UT Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas, Texas Morie A Gertz, MD, MACP Consultant, Hematology Mayo Clinic Rochester, Minnesota Irene M Ghobrial, MD Professor of Medicine Lavine Family Chair of Preventative Cancer Therapies Director, Center for Prevention of Progression of Blood Cancers Director, Translational Research in Multiple Myeloma Director, Clinical Investigator Research Program Director, Michele and Steven Kirsch Laboratory Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts Peter Voorhees, MD Professor of Medicine Chief, Plasma Cell Disorders Division Director of Medical Operations and Outreach Services Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute, Atrium Health Charlotte, North Carolina Moderator Robert Z Orlowski, MD, PhD Florence Maude Thomas Cancer Research Professor Department of Lymphoma and Myeloma Professor, Department of Experimental Therapeutics Director, Myeloma Section Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme.
Program Schedule — Eastern Time 3:00 PM – 3:15 PM — Registration and Snacks 3:15 PM – 5:15 PM — Educational Meeting MODULE 1: Contemporary Treatment Planning for Newly Diagnosed Multiple Myeloma (MM) MODULE 2: Integration of Novel Agents into the Current Management of Relapsed/Refractory (R/R) MM — PART 1 MODULE 3: Integration of Novel Agents into the Current Management of R/R MM — PART 2 MODULE 4: Chimeric Antigen Receptor T-Cell Therapy in MM MODULE 5: Novel Investigational Agents and Strategies Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Anderson — Advisory Committee, Consulting Agreements and Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides; Data and Safety Monitoring Board/Committee: Prothena. Dr Gertz — Advisory Board: Ionis Pharmaceuticals; Consulting Agreements: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena; Data and Safety Monitoring Board/Committee: AbbVie Inc, Celgene Corporation; Honoraria: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme; Stock Options: Aurora Biopharma. Dr Ghobrial — Advisory Committee: Amgen Inc (Europe), Aptitude Health, Bristol-Myers Squibb Company, GlaxoSmithKline, GNS Healthcare, Janssen Biotech Inc, Mind Wrap Medical LLC, Pfizer Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc (Europe), Aptitude Health, Binding Site, Bristol-Myers Squibb Company, Celgene Corporation, Cellectar Biosciences Inc, CohBar, Curio Science, DAVA Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, GNS Healthcare, Huron, Janssen Biotech Inc, Janssen Central America and Caribbean, Karyopharm Therapeutics, Magenta Therapeutics, Menarini Silicon Biosystems, Mind Wrap Medical LLC, Multiple Myeloma Research Foundation, Oncopeptides, Pfizer Inc, PureTech Health, Sanofi Genzyme, Sognef, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc; Spouse: CMO and equity holder of Disc Medicine (private company, not publicly traded). Dr Voorhees — Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Pfizer Inc, Sanofi Genzyme; Consulting Agreements: Amgen Inc, Secura Bio; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company, Karyopharm Therapeutics.MODERATOR — Robert Z Orlowski, MD, PhD – Advisory Committee: Amgen Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Clinical Research: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Laboratory Research: BioTheryX Inc, Heidelberg Pharma, Pfizer Inc; Ownership Interest: Asylia Therapeutics Inc (founder with equity interest and director, scientific advisory board). RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme. Omni Atlanta Hotel at CNN Center Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 2:45 PM on Friday, December 10th. If you are interested in attending, please visit our registration desk located outside the International Ballroom (E-F) - North Tower (M2 Floor) of the Omni Atlanta Hotel at CNN Center hotel (190 Marietta St NW) within walking distance of the Georgia World Congress Center. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the ASH Conference. Registration for live broadcast
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
|